Related Experiment Videos
Imiquimod 5% cream for keloid management
1Department of Dermatology and Cutaneous Surgery, University of Miami School of Medicine, FL 33136, USA. bberman@med.miami.edu
Summary
Topical imiquimod 5% cream effectively prevents keloid recurrence after surgical excision. This adjuvant therapy offers a promising solution to reduce the high rate of keloid regrowth.
Area of Science:
- Dermatology
- Wound Healing
- Adjuvant Therapies
Background:
- Keloid treatment remains a significant clinical challenge.
- High recurrence rates (50%) necessitate novel adjuvant therapies post-excision.
- Effective prevention strategies are crucial for improved patient outcomes.
Purpose of the Study:
- To outline the application of imiquimod 5% cream for keloid recurrence prevention.
- To review the scientific basis and clinical data supporting imiquimod use in keloid management.
Main Methods:
- Review of scientific literature and clinical case studies.
- Evaluation of imiquimod 5% cream's efficacy as an adjuvant therapy.
- Analysis of its role in post-surgical keloid management.
Main Results:
- Imiquimod 5% cream demonstrates potential in reducing keloid recurrence.
- Clinical experience suggests a favorable safety and efficacy profile.
- Evidence supports its use as a post-operative intervention.
Conclusions:
- Topical imiquimod 5% cream is an effective strategy to decrease keloid recurrence.
- This treatment offers a viable option for preventing post-surgical keloid regrowth.
- Further research may solidify its role in keloid management protocols.